Since its creation in 1953, the Fifty Fathoms has been the archetypal modern diver’s watch. Sixty years later, two new models join a fabulous lineage that has earned iconic status and Blancpain has chosen to celebrate the anniversary with a dedicated exhibition and press conference.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60646-blancpain
For Spring-Summer 2016, Maison Roger Vivier has entrusted one of its icons line to celebrity Stylist Camille Seydoux: Prismick. A friend of the house, this young woman has dreamed up a version all of her own: a capsule collection entirely in denim.
Six pieces make up this perfect wardrobe: platform sandals, ankle boots, a shoulder bag, a bucket bag, a backpack and a sneaker. Camille melds her creativity with the Roger Vivier legacy. She says:
"We decided that my collection would be dedicated to the Prismick line created in 2012, which is one of my favourites. I began by attentively exploring my own Prismick bag, which is in a melting fade of black and grey. I wanted to work on the idea of facets that make up grades of shading. I looked through the Maison's archives and then I thought of denim. It's a fabric that naturally burnishes. Denim is both classic and modern, and significant detail, is very resistant."
Camille grew up in fashion's inner circle. She opened her own art gallery at the age of 25. Today, she is revolutionising the role of stylist by working hand-in-hand with couture house studios to design bespoke dresses for actresses. For Roger Vivier, she brought her own touch of impertinence: "Denim can be worn with everything and can tone down an outfit. This capsule collection shakes up the look. "
To view the multimedia release go to:
http://www.multivu.com/players/uk/7776151-prismick-denim-camille-seydoux-roger-vivier/
In recent years there has been a shift in the understanding of cancer. Immunotherapy with vaccines has been emerging as the most promising direction towards a decisive improvement of treatment outcomes.
The Dendritic Cell Vaccine has received FDA approval for prostate cancer and trials are now under way for a variety of other cancers. These vaccines are usually administered on their own.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64654-issels-integrative-immunotherapy-for-standard-therapy-resistant-cancers
Following FDA approval of the AspireSR® generator for the VNS Therapy® system in June 2015, more than a thousand patients with drug-resistant epilepsy across the United States have received this new treatment option. Many of these patients are experiencing benefits which have positively impacted their lives – and are sharing their stories during Epilepsy Awareness Month with the hope of encouraging others to seek new treatments for drug-resistant epilepsy. Numerous hospitals nationwide have begun providing the AspireSR device to patients with drug-resistant epilepsy – a condition that affects as many as one-third of people with epilepsy, causing them to have seizures in spite of treatment with antiepileptic medications.
The VNS Therapy system is a minimally invasive option in which a medical device is placed under the skin in the upper chest area during an outpatient procedure. The device sends mild electrical pulses through the vagus nerve to areas of the brain known to be associated with seizures. The new AspireSR generator takes the VNS Therapy technology a step further – detecting relative heart-rate increases that are often associated with seizures in people with epilepsy and providing responsive stimulation in an attempt to stop and shorten seizures and improve recovery.
To view the multimedia release go to:
http://www.multivu.com/players/English/7651751-livanova-aspiresr-treatment/
LivaNova PLC (NASDAQ:LIVN; LSE: LIVN) (“LivaNova” or the “Company”), a market-leading medical technology and innovation company, today recognizes that more than one million people in the United States with drug-resistant epilepsy continue to be treated unsuccessfully with drugs, despite the proven effectiveness of non-drug treatment options. LivaNova’s VNS Therapy®, for example, is a medical device treatment specifically designed for people with drug-resistant epilepsy that is already used by more than 85,000 people around the world.
One in three people with epilepsy has the type that is not well controlled with drugs, called drug-resistant epilepsy. For those people, prescribing more medicine is usually not the most effective option. In fact, research shows that if you haven’t found seizure freedom after your first two drugs, there is a 95 percent chance that no drug or combination of drugs will result in seizure freedom.
“Despite what we know about drug-resistant epilepsy, the majority of people affected by this condition will continue to be prescribed additional medications instead of being evaluated for surgery or seen in a specialized epilepsy facility,” said Jason Richey, president of LivaNova’s U.S. Region and general manager of the Neuromodulation Business Franchise. “This treatment gap means over one million individuals in the U.S. with undertreated epilepsy remain at risk for dangerous side effects of continued seizures, including injury, depression, memory issues and death.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7966451-livanova-vns-therapy-epilepsy/
A ten-month clinical trial at Sentara Leigh Hospital in Norfolk, Virginia has determined that hard surfaces and linens infused with copper oxide compounds contributed to an 83% reduction in C-difficile and a 78% overall reduction in a host of multi-drug resistant organisms (MDROs) including C-diff, MRSA and VRE in a real-world clinical environment. These results occurred in a hospital with a robust protocol for managing infection risk certified by the health care accrediting body DNV-GL Healthcare.
The results of the trial were published in the peer-reviewed American Journal of Infection Control on Sept. 28, 2016 and will be presented at the annual conference of the Infectious Disease Society of America in New Orleans, Louisiana on October 27, 2016.
To view the multimedia release go to:
http://www.multivu.com/players/English/7955751-sentara-healthcare-infections-copper-clinical-trial/
Q&Q SmileSolar, known for its fun, color-driven and eco-friendly watches, unveils a digital campaign video filmed and animated by Cait Davis of Springtime Jellyfish. The video brings the brand’s core values to life in a fresh, modern way. Watches are available to purchase via the brand’s online store at store.smile-qq.com.
The Q&Q SmileSolar hero video highlights two of the brand’s most popular styles – the 20 Bar ($60 retail) and Mini ($40 retail) - that are completely solar-powered, keeping them operating up to approximately three-and-a-half months after one single charge. The watches are also all eco-friendly – the strap and case incorporate recycled materials – and each have a durable water-resistant casing as well.
The video also gives nod to the brand’s commitment to Table for Two, a non-profit that delivers school meals to children in Africa and Asia. A percentage of sales from each watch goes to support the cause. To date, Q&Q has donated over 131,000 meals.
To view the multimedia release go to:
https://www.multivu.com/players/English/7886551-q-and-q-smilesolar-hero-video
BLACK+DECKER™ announces new powered kitchen and bathroom scrubbers for cleaning without all the work. The GrimeBuster™, GrimeBuster™ Pro, and ScumBuster® Pro motorize scrubbing in order to agitate surface materials, eliminating the typical “elbow grease” that manual cleaning requires.
The GrimeBuster™ ($14.99 MSRP) and GrimeBuster™ Pro ($29.99 MSRP) quickly clean kitchen surfaces, dirty pots and pans, sinks, microwaves, and more. They are lightweight and each feature an ergonomic design. With a slip-resistant grip, they are also submersible in water. Each scrubber comes with two dishwasher-safe scrubbing attachments – one with a non-scratch sponge and one with nylon bristles. Heavy-duty sponge and bristle brush attachments will be sold separately. The GrimeBuster™ is powered by four included alkaline batteries. The GrimeBuster™ Pro has added features, including a longer handle and a charging dock that powers its long-lasting Lithium-Ion battery. The attractively designed GrimeBuster™ Pro can be left on the counter on its charging base until it’s time to clean again.
To view the multimedia release go to:
https://www.multivu.com/players/English/8005955-black-decker-powered-scrubbers/
Sally Hansen continues to lead in innovation by introducing its new Color Therapy products: a nail polish, top coat, and nail & cuticle oil, inspired by women’s desire to wear beautiful color while simultaneously caring for their nails. Sally Hansen’s Color Therapy nail polish contains a patented micro-delivery system that delivers an argan oil-enriched formula, resulting in intensive nourishment and instant moisture for healthier-looking nails. The Color Therapy nail polish needs no base coat so the oil complex can directly contact the bare nail. 9 out of 10 women experienced a noticeable improvement in their natural nails after wearing the Color Therapy nail polish. Vibrant tones, available in three magnificent palettes, glide on for a radiant, shiny finish with up to 10 days of fade-proof, chip-resistant wear. The Color Therapy nail polish provides the ultimate color that cares while you wear, with everything needed to restore nails without sacrificing luminous color.
Complete your manicure with the Color Therapy top coat and nail & cuticle oil, both formulated with the same argan oil contained in the nail polish. The top coat provides an ultra-glossy finish for extended wear, and the nail & cuticle oil, the ultimate in nail therapy, instantly makes nails and cuticles look healthier, restored, and rejuvenated.
To view the multimedia release go to:
http://www.multivu.com/players/English/7957151-sally-hansen-color-therapy-nail-polish/
MAKE UP FOR EVER, the professional makeup line of innovative and artistic products created for professional stage artists, makeup artists and makeup enthusiasts, announces a worldwide artistic collaboration with global pop sensation CHARLI XCX and reveals its new AQUA XL EYE PENCIL campaign.
CHARLI XCX’s bold, artistic and energetic stage presence exemplifies the creative spirit of MAKE UP FOR EVER and the performance of the AQUA XL collection. In 2016, MAKE UP FOR EVER joins CHARLI XCX in all her performances and artistic creations, from her live tour to makeup artistry for her video clips. A virtuoso of words and sound, CHARLI XCX has written several international hit songs including her double platinum single, “Boom Clap,” alongside co-penning music for renowned artists; Grammy nominated “Fancy” (Iggy Azalea), triple platinum selling “I Love It” (Icona Pop) and “Same Old Love” (Selena Gomez).
The AQUA line, upon which performers and their makeup artists have long relied, has become AQUA XL, taking the limits of makeup performance to new levels. MAKE UP FOR EVER is revamping one of its iconic products with a new high-performance formula: AQUA XL EYE PENCIL, the first of the AQUA XL line and specially designed for performers’ needs. AQUA XL EYE PENCIL are stage-proof and offer flawless makeup results, incredible stay-on power and high color intensity. As comfortable as it is easy to apply, the AQUA XL EYE PENCIL’s long wear waterproof formula is resistant to all stage conditions and perfect for real life-use.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7792251-make-up-for-ever-teams-up-with-charli-xcx/
GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today that The New England Journal of Medicine has published results from a Phase 3 study of Epidiolex® (cannabidiol) in children with Dravet syndrome.1 Epidiolex, GW’s lead product candidate and the potential first in a new category of anti-epileptic drugs, is a liquid formulation of purified, plant-derived cannabidiol (CBD), a non-psychoactive cannabinoid, which is being studied for the treatment of a number of rare, severe pediatric-onset epilepsy disorders. In the study, Epidiolex significantly reduced monthly convulsive seizure frequency compared to placebo in highly treatment-resistant children when added to existing treatment. Treatment with Epidiolex was generally well tolerated, with a safety profile consistent with prior open label experience.
To view the multimedia release go to:
https://www.multivu.com/players/uk/8109951-gw-pharmaceuticals-study-epidiolex/
At more than 60 percent quieter1, 30 percent lighter and 45 percent more compact than a standard generator2, the new Briggs & Stratton Q6500 QuietPower™ Series inverter generator3 introduces category-changing innovations to the generator market. Its fully-enclosed, impact-resistant shell significantly reduces noise and its lightweight compact design answers unmet needs among generator owners.
“We created a residential backup power source that drew upon the convenience and fuel efficiency inverters have brought to camping and tailgating events, but also increased the power output and value to serve the portable home backup market,” says Dan Roche, director of marketing, portable power and cleaning systems at Briggs & Stratton. “The Q6500 combines the best of inverter technology with enough wattage for total home power restoration.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8083851-briggs-stratton-q6500-quietpower-series-inverter-generator/
